(VOR) – Business Wire
-
PureTech Year End Update and Outlook for 2024
-
PureTech Health plc – Half-Year Report
-
PureTech Announces Annual Results for Year Ended December 31, 2022
-
PureTech Provides End of Year Report on Key Progress
-
PureTech Health plc – Half-Year Report
-
Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases
-
PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I
-
PureTech Founded Entity Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia
-
PureTech Health plc – Half-Year Report
-
PureTech Founded Entity Gelesis, the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp.
-
PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined with a Bi-Specific Antibody Therapy for Acute Myeloid Leuk
-
PureTech Founded Entity Vor Biopharma Closes Over $200M Initial Public Offering
-
PureTech Founded Entity Vor Biopharma Announces Pricing of Initial Public Offering
Back to VOR Stock Lookup
